Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Risk adjusted net present value: What is the current valuation of Merck's Vibostolimab?
Vibostolimab is a monoclonal antibody commercialized by Merck, with a leading Phase II program in Melanoma. According to Globaldata, it...
Vibostolimab by Merck for Non-Small Cell Lung Cancer: Likelihood of Approval
Vibostolimab is under clinical development by Merck and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData,...
Risk adjusted net present value: What is the current valuation of Merck's Vibostolimab?
Vibostolimab is a monoclonal antibody commercialized by Merck, with a leading Phase II program in Non-Small Cell Lung Cancer. According...